Cannabis Bioscience International Holdings News Releases

CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research

Mon, 20 Jul 2026 07:00:00 -0400

Houston, Texas--(Newsfile Corp. - July 20, 2026) - Alzheimer's disease is not only a scientific challenge; it is a human crisis affecting millions of patients, families, caregivers, and healthcare systems. Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) is responding through an intranasal nanoemulsion platform designed to explore new possibilities in neurodegenerative care through cannabinoid-based and natural-compound science.CBIH's invention centers on an intranasal medicine...

Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products

Wed, 15 Jul 2026 07:00:00 -0400

Houston, Texas--(Newsfile Corp. - July 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that the State of Texas has approved the Company's license to manufacture and distribute consumable hemp products. This approval turns years of vision, science, and preparation into action and marks the moment CBIH steps into the market and begins commercial distribution.The Company expects...

CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings

Mon, 06 Jul 2026 07:00:00 -0400

Houston, Texas--(Newsfile Corp. - July 6, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announces that Dante Picazo, Chief Executive Officer of the Company, has designated 500,000,000 shares of common stock from his personal holdings to honor the directors, employees, and key associates whose dedication, loyalty, and work have helped shape CBIH's journey and strengthen the Company through years of...

Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement

Mon, 22 Jun 2026 07:00:00 -0400

Houston, Texas--(Newsfile Corp. - June 22, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the beginning of a new commercial chapter for VitaCookies with the signing of its first licensing agreement. This milestone moves VitaCookies from internal development toward commercial execution, positioning the brand as a structured growth opportunity built on CBIH's formulations, operational...

CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research

Mon, 15 Jun 2026 07:00:00 -0400

Houston, Texas--(Newsfile Corp. - June 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading under the ticker symbol CBIH, today announced a new chapter in its PTSD-focused research journey, marked by the completion of its patent-related work and the continued exploration of the scientific relationship between cannabinoids and psilocybin in relation to trauma, memory, emotional regulation, and recovery.PTSD affects veterans, first responders,...

CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers

Mon, 08 Jun 2026 07:00:00 -0400

Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public biotechnology company trading under the ticker symbol CBIH, today announced that it has completed and submitted the required documentation as part of its Texas licensing process related to the planned commercialization of VitaCookies, its cannabinoid-formulated functional wellness cookie line. CBIH intends to move forward carefully, with a focus on licensing and franchising...

CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation

Mon, 01 Jun 2026 07:00:00 -0400

Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on cannabinoid biotechnology, applied research, and therapeutic innovation, today announced the completion of a patent-ready melanoma research program focused on cannabinoid science, oncology biology, aging-related cellular stress, and epigenetic regulation.The Company views this milestone as part of its broader strategy to build research-driven intellectual...

CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio

Wed, 21 Jan 2026 07:00:00 -0500

Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions.CBIH clarifies that this communication reflects a serious...

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence

Mon, 12 Jan 2026 07:00:00 -0500

Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding.CBIH confirms receipt of a communication from the Centers for Medicare &...

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition

Mon, 05 Jan 2026 07:00:00 -0500

Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Executive Order directed...